In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 268.1K | $2.0M | 2.95% | +7.8K | 2026-06-30 |
| Morgan Stanley | 233.9K | $2.0M | 2.58% | +12.2K | 2026-06-30 |
| Renaissance Technologies LLC | 171.1K | $1.0M | 1.88% | +19.3K | 2026-06-30 |
| Cresset Asset Management, LLC | 135.3K | $1.0M | 1.49% | -- | 2026-06-30 |
| Geode Capital Management, LLC | 72.3K | -- | 0.80% | +6.5K | 2026-06-30 |
| Dimensional Fund Advisors LP | 58.5K | -- | 0.64% | +2.4K | 2026-06-30 |
| Bleichroeder LP | 50.0K | -- | 0.55% | -51.6K | 2026-06-30 |
| Steadtrust LLC | 45.4K | -- | 0.50% | -9.0K | 2026-06-30 |
| Mesirow Financial Investment Management, Inc. | 42.5K | -- | 0.47% | -- | 2026-06-30 |
| Citadel Advisors LLC | 40.5K | -- | 0.45% | +4.8K | 2026-06-30 |
